Eliav Barr, Merck Research Laboratories chief medical officer

Mer­ck­'s Keytru­da plus TIG­IT com­bo proves less ef­fec­tive than chemo in open-la­bel lung can­cer study

Ahead of Keytru­da’s patent cliff in 2028, Mer­ck is try­ing to de­vel­op a va­ri­ety of com­bi­na­tion ther­a­pies that can ex­tend the megablock­buster’s po­ten­tial. But one …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA